Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Exclusion Criteria

• •Use or anticipated use of any medication prohibited in this study
• •Evidence of abnormal clinical laboratory values, vital signs, or electrocardiographic (ECG) results or the presence of abnormities in physical examination findings
• •The presence of anti-cholinergic effects (eg, dry mouth, urinary retention, narrow angle glaucoma)
• •QTcB of \>500 msec on both the pre-dose and post-dose ECG
• •Women who are pregnant, intend to become pregnant, or are breast-feeding
• •A life expectancy of less than 1 year
• •Noncompliance with IP dosing and/or attending clinic visits during the lead-in study
• •Significant interruption of double-blind therapy during the transition from the lead-in study into the extension study.